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Abstract
Introduction:  Vascular calcification independently predicts cardiovascular disease, the major cause of death 
in Chronic Kidney Disease (CKD) patients. Coronary Artery Calcium Score (CACS) is a marker for atherosclerotic 
plaque burden, vascular calcification and has been shown to be a predictor of incidence of myocardial infarction and 
death from Cardiovascular (CV) disease. 
Objectives: The aim of the study was to evaluate factors influencing CV mortality in a group of Peritoneal 
Dialysis (PD) patients during a six year observation period. 
Patients and methods: The study included 53 patients with no symptoms of CV disease (25 women, 28 men; 
mean age of 52 ± 12 years) treated with PD for a median period of 24 months. Baseline Framingham Risk Score 
(FRS) was assessed and CACS was measured using Multi-Row Spiral Computed Tomography (MSCT). Laboratory 
measurements included high sensitive C-reactive protein (hsCRP), osteoprotegerin (OPG), fibroblast growth factor 
23 (FGF23), osteopontin (OPN), osteocalcin (OC), intact parathyroid hormone (iPTH), total calcium (Ca) and 
phosphates (Pi). The data concerning mortality was collected over a 6 year period.
Results: During the six year observation period, 24 (45%) patients died, including 19 due to CV causes. Median 
overall survival was 72 months (lower quartile, 17 months). CACS was a significant predictor of all-cause and 
CV mortality both in simple analysis (HR=1.03 per 100 Agatston units, p=0.02 and HR=1.05, p=0.003), as well 
as in a multiple model adjusted for age of patients, dialysis duration, weekly creatinine clearance, Ca x Pi, iPTH, 
OPG, hsCRP and FRS (HR=1.04, p=0.02 and HR=1.05, p=0.01). The value of 800 Agatston units significantly 
differentiated the group into those with higher and lower risk for CV death (p=0.04). Age and FGF23 concentration 
were independent predictors of CACS. Also, hsCRP and FRS significantly predicted all-cause and CV mortality in 
simple Cox regression (HR=1.04, p=0.002 and HR=1.04, p=0.003; HR=1.14, p=0.047 and HR=1.23, p=0.01) as well 
as in a multiple model (HR=1.05, p=0.002 and HR=1.05, p=0.01; HR=1.23, p=0.01 and HR=1.33, p=0.004). Adding 
CACS to FRS and hsCRP significantly improved the prediction of cardiovascular mortality (p=0.02).
Conclusions: Coronary calcium imaging is a non-invasive method of CV risk stratification that can accurately 
identify high-risk asymptomatic dialysis patients at the start of dialysis. The assessment of CACS together with 
inflammatory markers and conventional CV risk factors (FRS) may contribute to early diagnosis, prevention and 
reduction of deaths from CV disease in dialysis patients. Among the markers of bone disease, FGF-23 (a regulator 
of phosphorus metabolism) may be an early predictor of vascular calcification among dialysis patients.
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Introduction
Vascular calcification independently predicts cardiovascular 
(CV) disease, the major cause of death In Chronic Kidney Disease
(CKD) patients. Coronary Artery Calcium Score (CACS) is a marker
for atherosclerotic plaque burden and has been shown to predict the
incidence of myocardial infarction and death from CV disease. CKD
leads to increased calcium score secondary to accelerated progression
of atherosclerosis, as well as changes in calcium homeostasis [1].
Vascular calcification is one of the major problems among CKD
patients and contributes to the increased risk of CV events by a
variety of mechanisms including increased arterial stiffness due to
medial calcification or plaque vulnerability linked with atherosclerotic
calcification [2]. Risk factors for atherosclerosis and coronary artery
disease, including age, sex, dyslipidemia, diabetes, obesity, smoking
habit, high blood pressure, family history of early onset CV disease,
inflammation and renal function are used to predict absolute risk 
for CV disease both in CKD patients and general population [3]. 
Emerging nontraditional risk factors for risk assessment include 
high sensitive C-reactive protein (hsCRP), fibrinogen, lipoprotein A, 
interleukin-6 (IL-6) and plasminogen activator inhibitor (PAI-1). The 
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performed with the Simpson’s biplane method, using Vivide 7 GE 
Healthcare machine.
Mean Arterial Pressure (MAP) was calculated from the formula: 
MAP = (systolic blood pressure + 2 × diastolic blood pressure)/3. 
Ten-year risk of coronary artery disease (CAD) was calculated by the 
Framingham Risk Score (FRS) in accordance with published guidelines 
[10].
Data on mortality were collected during the 6 year (72 months) 
period. All deaths occurred in the hospital and causes of death were 
determined using disease history documentation. 
The study was approved by the Bioethics Committee of the 
Jagiellonian University and all patients signed an informed consent for 
their participation.
Statistical analysis 
Number of patients (percentage of the group) was reported 
for categorical variables and mean ± standard deviation or median 
(lower-upper quartile) for continuous variables with normal or non-
normal distributions, as appropriate. The Shapiro-Wilk test was used 
to assess normality. Simple correlations were studied using Spearman 
coefficient. Multiple linear regression models were constructed using 
predictors significant in simple analysis, after log-transformation of 
the right-skewed variables. Survival curves were computed using the 
Kaplan-Meier method and compared with log-rank test. Patients 
who underwent renal transplantation during the study period were 
considered as censored observations. Unadjusted and adjusted 
Hazard Ratios (HR) for all-cause and cardiovascular mortality were 
estimated using Cox proportional regression and were reported with 
95% confidence intervals (95% CI). HR per one unit increase was 
reported unless otherwise stated. Multiple Cox models were adjusted 
for predefined set of confounders, listed in the Results section. Nested 
Cox models were compared with log-likelihood statistic. Results were 
considered significant at p ≤ 0.05. Statistical 10 package (StatSoft, Inc., 
Tulsa, USA) was used for computations.
Results
Clinical characteristics of the studied group and the concentrations 
of selected bone markers together with the reference ranges are 
presented in Table 1.
CACS correlated with age of patients, FRS as well as with OPG and 
FGF23 levels. Other bone markers (OC, OPN) did not correlate with 
CACS, nor did Ca or Pi levels, Ca x Pi product and iPTH concentration 
(Table 2). Also, CACS did not correlate with the parameters of dialysis 
adequacy. In a multiple model, including age, FRS, log(OPG) and log 
(FGF23) as the independent variables, age and log(FGF23) were shown 
to be independent predictors of log (CACS) (beta=0.51, p=0.001 and 
beta=0.45, p=0.003, respectively). The model explained 41% of log 
(CACS) variance (p=0.001 for the model).
During the six years follow-up, 16 patients (30%) experienced non-
fatal CV events, including acute myocardial infarction in 13 patients 
and ischemic stroke in 3. Twenty four patients (45% of the group) died 
during the study period, including 19 patients (79%) due to CV causes 
(Table 1), i.e. sudden cardiac death (7 patients), myocardial infarction 
(5 patients), cerebral stroke (3 patients), chronic heart failure and 
peripheral vascular disease (2 patients each). Other causes of death 
in these patients included: encapsulating peritoneal sclerosis (EPS) (3 
patients) and infections (2 patients). The studied group included 19 
patients (36%) who were transferred to hemodialysis during the study 
role of inflammation in the pathogenesis of several complications of 
CKD is well documented [4]. In particular, several markers have been 
associated with CV morbidity and vascular calcification. They include: 
hsCRP, IL-6, markers of oxidative stress as well as bone turnover with 
some evidence of a cause-effect relationship [5-7].
Coronary calcification is a marker of atherosclerosis and evaluation 
of CACS by Multi-Row Spiral Computed Tomography (MSCT) has 
been recognized as useful strategy to initiate or intensify treatment 
of atherosclerosis. Besides the risk of CV disease, CACS has been 
demonstrated to be associated with the risk of complication during 
PCI, including arterial perforation, dissection and resultant stent 
thrombosis [2]. The non-invasive test such as CACS used for CV 
disease evaluation in CKD patients has the purpose of identifying 
Coronary Artery Disease (CAD) and evaluating the risk of CV 
events and death. CACS identifies calcified plaques using scattered 
X-rays; it is a marker of atherosclerosis that may improve current risk 
assessment when added to traditional risk factors [8,9]. The aim of the 
study concerning Peritoneal Dialysis (PD) patients was to evaluate the 
association of CACS with long-term (6 years) total and CV mortality 
in relation to traditional CV risk factors, inflammatory markers and 
vascular calcification parameters.
Patients and Methods
The study group consisted of 53 asymptomatic patients (25 women, 
28 men) with a mean age of 52 ± 12 years, treated with PD for a median 
period of 24 months (range 4 to 100 months). Patients were included 
according to the following criteria: age above 18 years, continuous 
methods of PD (CADO, CCDO), stable clinical dialysis course for at 
least 2 months before inclusion into the study, negative history for 
cardiovascular diseases and neoplasms and no active viral infection 
(HIV, hepatitis type B or C). PD patients were qualified during routine 
hospital visits and on this same day CACS was performed, as well as 
collection of blood samples for biochemical tests. The concentrations 
of albumin, fibrinogen, total cholesterol, LDL-cholesterol, HDL-
cholesterol, Triglycerides (TG), glucose, Osteoprotegerin (OPG), 
Fibroblast Growth Factor 23 (FGF23), Osteopontin (OPN), Osteocalcin 
(OC), intact Parathyroid Hormone (iPTH), total calcium (Ca) and 
Phosphates (Pi) and peripheral blood counts were measured. Peritoneal 
dialysis dose was assessed using Weekly Creatinine Clearance (WCrCl). 
An echocardiography was performed in each patient within 1 month 
from inclusion.
Routine biochemical tests were carried out on automatic biochemical 
analyzers: Hitachi 917 and Modular P (Roche Diagnostics, Mannheim, 
Germany). Hematology parameters were measured using Sysmex XE 
2100 Hematological Analyzer (Sysmex Corp. Japan). Concentrations 
of hsCRP were measured using the immunonephelometric method 
on Nephelometer BN II (Siemens Healthcare Diagnostics, Germany). 
Bone disease markers were determined using ELISA immunoassay. 
We used the following sets of reagents: OPG (Biomedica, Wien), FGF 
23 (Immutopics, USA) OC (METRA, Germany), OPN (Quantikine 
Human Osteopontin Elisa kit, R&D Systems). All measurements 
using ELISA micro-plates were performed on the Automatic Micro 
ELISA Reader ELX808 (BIO-TEK® Instruments, Inc., Vermont, USA). 
Body mass index (BMI) was calculated using the Quetelet formula. 
The assessment of calcifications in coronary arteries was performed 
by MSCT (Somaton Plus 4 Volume Zoom), using a calcium scoring 
program (Siemens Company, Nürnberg, Germany). The Agatston 
scale was employed to interpret the results, using CACS expressed 
in Hounsfield units (HU). Transthoracic echocardiography was 
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period (3 of them died due to CV causes during the follow-up). Eleven 
patients (21%) underwent successful renal transplantation and were 
treated as censored observations in survival analysis. Median of overall 
survival in the whole studied group was 72 months (lower quartile: 17 
months). 
Both all-cause and CV deaths were associated with higher CACS 
values. Especially, patients who died due to CV causes had much 
higher CACS comparing to the rest of the group: 778 (73-2476) versus 
62 (0-515), p=0.03. CACS value of 800 Agatston units significantly 
differentiated the group into those with higher and lower risk for CV 
death (p=0.04). Figure 1 shows CV survival curves of patients with 
CACS over 800 Agatston units versus those with lower values. 
CACS significantly correlated with total and CV mortality in PD 
patients in simple Cox regression. The hazard ratios per 100 Agatston 
units’ increase in CACS were as following: HR=1.03 (1.01-1.07), 
p=0.02 for all-cause mortality and HR=1.05 (1.02-1.08), p=0.003 for 
CV mortality. Of the bone markers studied, only OPG significantly 
correlated with survival in simple analysis [HR=1.09 (1.004-1.19), 
p=0.04 for overall survival]. Also, CRP [HR=1.04 (1.01-1.07), p=0.003 
and HR=1.04 (1.01-1.07), p=0.006] and FRS [points: HR=1.13 (1.001-
1.30), p=0.049 and HR=1.21 (1.03-1.42), p=0.02; ten-year risk: HR=1.04 
(1.001-1.08), p=0.04 and HR=1.05 (1.01-1.10), p=0.02] appeared to 
be significant predictors of all-cause and CV mortality in simple Cox 
regression. FRS was significantly higher in patients who died from CV 
Peritoneal dialysis patients 
(N=53) Average values
* Minimum-
maximum Reference values
Age, years 52 ± 12 19-75 -
Gender: men/women 28 (53%)/25 (47%) -
Dialysis treatment 
duration, months 24 (15-51) 4-100 -
Observation period, 
months 60 (9-72) 1-72 -
All-cause mortality 24 (45%) - -
Cardiovascular mortality 19 (36%) - -
Active smoking 11 (21%) - -
Diabetes 12 (23%) - -
Hypertension 46 (87%) - -
Left ventricular ejection 
fraction, % 64 (60-66) 45-74 55-70
Left ventricular mass, g 244 ± 78 102-423 F: 67–162M: 88–224
Left ventricular mass 
index, g/m2 138 ± 43 55-246
F: maximum to 110
M:maximum to 125
FRS, points 8 (5-10) 8-16 -
FRS, ten-year risk, % 10 (6-16) 1-37 -
BMI, kg/m2 25.2 ± 4.2 17.2-34.2 20-25
Systolic blood pressure, 
mmHg 149 ± 18 105-180 < 130
Diastolic blood pressure, 
mmHg 90 ± 12 60-115 < 80
Mean arterial pressure, 
mmHg 110 ± 11 87-133 75-100
Hemoglobin, g/dL 11.9 ± 1.7 7.7-15.3 12-17
Fibrinogen, g/L 6.0 ± 1.3 2.9-8.6 1.8-3.5
WBC, x103/µL 7.56 ± 2.44 2.77-12.36 4-10
hsCRP, mg/L 4.18 (1.29-11.40) 0.16-35.9 <3.17
Albumin, g/L 38 ± 5 20-47 35-50
Fasting glucose, mmol/L 4.7 (4.4-5.4) 3.4-15.4 3.3-5.6
Total cholesterol, mmol/L 5.54 ± 1.15 3.35-9.02 3.2-5.2
LDL-cholesterol, mmol/L 3.25 ± 0.93 1.45-6.35 0.2-3.4
HDL-cholesterol, mmol/L 1.41 ± 0.33 0.84-2.24 0.9-3.0
Triglycerides, mmol/L 1.95 ± 0.81 0.59-3.66 0.2-2.3
Ca, mmol/L 2.30 ± 0.22 1.59-2.67 2.1-2.4
Pi, mmol/L 1.78 ± 0.48 0.79-2.59 1.1-1.8
Ca x Pi, mmol2/L2 4.11 ± 1.27 1.81-5.99 < 4.4
iPTH, pg/mL 437 (198-836) 3-2474 12-72
FGF23, RU/mL 3013 (854-12015) 14.9-38798 no data
OPG, pmol/L 9.69 (8.44-13.18) 3.87-27.48 2.5-12.8
**
OC, ng/mL 65.2 (38.9-70.3) 10.6-72.5 F: 3.7-10.0 M: 3.4-9.1**
OPN, ng/mL 1475 (1038-1870) 559-3092 49.2-175.0
**
CACS, Agatston units 92 (0-761) 0-4555 0-100
WCrCl, L/week/1.73 m2 66.7 (58.8-85.7) 43.2-213.8 > 45.0
* Number of patients (percent) is given for categorical variables; mean ± standard 
deviation or median (lower-upper quartile) for continuous variables with normal or 
non-normal distribution, respectively.
** Reference ranges established by manufacturer.
Table 1: Characteristics of the study group at the beginning of the study and data 
on mortality during follow-up period.
Independent variable Spearman correlation coefficient P
Age 0.41 0.002
Dialysis therapy duration 0.17 0.2
FRS, points 0.37 0.007
FRS, ten-year risk 0.28 0.04
Ca 0.22 0.1
Pi 0.08 0.6
Ca x Pi 0.12 0.4
hsCRP 0.27 0.053
iPTH -0.03 0.8
FGF23 0.43 0.002
OPG 0.39 0.004
OC -0.14 0.3
OPN -0.02 0.9
Table 2: Simple correlations of selected variables with CACS.
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Figure 1: Kaplan-Meier survival curves for cardiovascular mortality in patients 
with CACS above 800 Agatston units (solid line) versus patients with lower 
CACS values (dashed line). Total numbers at risk at baseline, after 3 and 6 
years are shown at the bottom of the graph.
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causes [FRS, points: 10 (8-11) versus 7 (3-9); p=0.001; FRS, ten-year 
risk: 13 (10-25) versus 8 (4-13); p=0.002].
In multiple models, CACS was shown to predict all-cause and 
CV mortality independently of age of patients, dialysis therapy 
duration, weekly creatinine clearance, Ca x Pi, iPTH, CRP and OPG 
concentrations as well as FRS (Table 3). 
Finally, we compared three Cox models to predict CV mortality. 
The basic model included FRS (points) as the independent variable; the 
R2 for this model was 0.29. Adding hsCRP to the model increased the R2 
value to 0.45 (p=0.02 in log-likelihood test). Adding CACS to the model 
as the third independent variable resulted in further improvement in 
CV mortality prediction (R2=0.60; p=0.02 in log-likelihood test).
Discussion
Our study presents comprehensive comparison of biochemical 
and clinical data with calcification status (CACS) assessed by MSCT. 
In CKD patients, the prevalence of CAD and the incidence of major 
adverse CV events are very high. In our study both all cause and CV 
deaths were associated with higher CACS values. At the threshold of 
800 Agatstone units, CACS identified a subgroup with a high risk of 
CV mortality. The importance of CACS in determining the risk of 
CV mortality is also confirmed by other researchers [9,11-14]. In the 
study of Budoff et al., CACS values over 400 and especially over 1000 
Agatston units were associated with high risk for all-cause mortality 
(relative risk 5.78 and 9.36, respectively) [15]. The study group 
consisted of 25,253 asymptomatic individuals referred by their primary 
physician for Coronary Artery Calcium (CAC) scanning in order 
to assess CV risk. Similarly, the 1-year incidence of hard CV events 
(defined as myocardial infarction or coronary death) demonstrated by 
Wayhs et al. in patients with CACS above 1000 was 25% [16]. Lee et 
al. demonstrated high cardiac events rates in CKD patients with both 
coronary artery stenosis and high CACS at the start of dialysis [17]. In 
the other study, Roe et al.  evaluated 112 asymptomatic renal transplant 
recipients with no prior history of coronary artery revascularization 
or myocardial infarction and assessed coronary calcifications early 
post-transplant and 18 months later [18]. Higher baseline CACS was 
associated with CV events and mortality, in particular patients with 
CACS below 100 Agatston units had better survival rates. A quarter 
(25.9%) of recipients had CAC progression. Coronary calcification 
progression also predicted CV events and mortality after adjustment 
for diabetes, age, dialysis vintage and presence of CAC at the time 
of transplantation. The St. Francis Heart Study included over 4,900 
patients who were followed for 4.3 years [19]. CACS above 384 Agatston 
units was associated with a 30-fold increased risk for myocardial 
infarction or CV death, independently of FRS and hsCRP. Also, in 
the Prospective Army Coronary Calcium Project, in which 2000 
younger participants were evaluated with electron beam tomography 
and followed prospectively for a mean period of 3 years, CACS was 
associated with a 12-fold increased risk for hard CV events even after 
controlling for the FRS [20].
Consistently, in our study, participants with high CACS had higher 
CV risk and the association was independent of the age of patients, 
dialysis duration, weekly creatinine clearance, CRP, Ca x Pi product, 
iPTH and OPG concentration as well as FRS. Moreover, the addition of 
CACS to FRS and hsCRP significantly improved CV risk assessment in 
our group of PD patients. In addition, our study revealed a significant 
association of baseline hsCRP and FRS with total and CV mortality in 
dialysis patients. Association of inflammation with mortality in dialysis 
patients is well known [21-23]. The mechanisms responsible for 
vascular calcification include inflammation as well as bone and mineral 
disturbances. We did not find a correlation between CACS and hsCRP 
(borderline significant), as well as markers of bone turnover, except for 
FGF23 and OPG. Only FGF23 was shown to be an independent predictor 
of CACS in a multiple model. Our results are in accordance with the 
study of Morena et al., demonstrating the relationship between FGF23, 
OPG and CAC in CKD patients [24]. The univariate analysis showed 
that high OPG was significantly associated with moderate CAC. Severe 
CAC was only associated with high phosphate fractional excretion and 
high FGF23. In another study, Khan et al. enrolled 99 CKD patients 
initiating hemodialysis in which MSCT was measured at baseline and 
in 67 study participants after 1 year of hemodialysis treatment. FGF23 
was not associated with baseline CAC, but significantly correlated with 
CAC progression [25]. This association persisted after adjustment for 
hsCRP, 25-OH vitamin D levels and the use of phosphorus binders. 
In the study of Masai et al., serum FGF23 levels were associated 
with coronary calcification independently of classical risk factors, 
adipocytokines and inflammatory markers in patients without CKD 
and diabetes mellitus [26]. Among calcium/phosphate metabolism 
markers, as in our study, FGF23 showed significant correlation with 
Agatston score and in multivariate linear regression analysis, only 
age and FGF23 were independently associated with the Agatston 
score. Authors postulated that FGF23 may also have a direct effect 
on progression of CAC. On the other hand, several studies reported 
that FGF23 is independently associated with aortic calcification in 
HD patients [27,28]. Therefore, extraordinary accumulation of FGF23 
in serum may enable inhibition of the calcification process at vessel 
walls. Osteoblastic transformation and production of several bone 
proteins were demonstrated in the intima and media of calcified blood 
vessels obtained from dialysis patients [29]. Another hypothesis is that 
FGF23, which is also a bone-associated protein, may be a marker of 
the volume of the tissue producing it (i.e. the proliferating vascular 
osteoblasts and osteocytes). This may provide an explanation for the 
repeatedly demonstrated reproducible correlation of ‘single’ FGF23 
measurements with the severity of vascular calcification as well as 
atherosclerosis [30,31]. Similar results were obtained in our study.
In our study OPG was associated with CAC score only in 
simple analysis. However, of bone turnover markers, only the OPG 
significantly correlated with mortality in simple analysis. OPG is 
known to regulate bone mineral metabolism but it is also associated 
with inflammation, CV disease and mortality. In the study of Koo et al., 
OPG levels were positively correlated with inflammatory markers and 
Independent variable
All-cause mortality Cardiovascular mortality
HR (95% CI) p HR (95% CI) P
CACS*, 100 Agatston units 1.04 (1.01-1.08) 0.02 1.05 (1.01-1.10) 0.01
hsCRP, mg/L 1.05 (1.02-1.09) 0.002 1.05 (1.01-1.09) 0.01
FRS, points 1.23 (1.05-1.44) 0.01 1.33 (1.10-1.61) 0.004
*In case of CACS, HR per 100 Agatston units’ increase is given.
Table 3: Significant predictors of all-cause and cardiovascular mortality in multiple Cox regression. The models additionally included age of patients, dialysis therapy 
duration, weekly creatinine clearance, Ca x Pi, iPTH and OPG as independent variables.
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negatively correlated with nutritional status [32]. CV events occurred 
in 51 of the 176 patients on peritoneal dialysis recruited to the study 
during a 5 year observation period. Newly developed CV events were 
significantly more common in patients with higher OPG levels. Cox 
regression analysis revealed that higher OPG level was a significant 
risk factor for CV events even after adjustments for demographic 
and biochemical parameters. Increased serum concentration of OPG 
can serve as a surrogate marker of progression of atherosclerosis and 
severity of vascular calcification in CKD patients [33-36]. Our results 
are in accordance with the study of Kurnatowska et al. demonstrating 
the relationship between serum OPG and CAC, as well as common 
carotid artery intima-media (CCA-IMT) [37]. At baseline, 70% of 
the HD patients presented detectable CAC. The patients without 
calcification at baseline remained calcification free at 30 months and 
presented lower serum OPG and FGF23 than those with CAC. A 64.4% 
progression of CAC was observed in all patients with CAC at baseline. 
Additionally, both increased CAC as well as CCA-IMT correlated 
positively with baseline and follow-up serum OPG. The patients who 
died had significantly higher baseline CAC and serum OPG. Increased 
levels of OPG can represent a response to a mineral and bone disorders 
in CKD patients, it may constitute a compensatory mechanism or 
perform protective functions [38,39]. 
Summarizing, although limited by the low number of participants, 
our study provides further evidence that CACS examination may 
improve CV risk assessment in CKD patients in addition to hsCRP and 
traditional CV risk factors represented by FRS. Better identification 
of high-risk patients exerts the possibility of early prevention of these 
diseases and may lead to reduced mortality from CV disease in the 
population of dialysis patients. FGF23, a regulator of phosphorus 
metabolism, is strongly associated with CACS and may be a simple 
candidate biomarker of vascular calcification among dialysis patients.
Conclusion
Coronary calcium imaging is a non-invasive method of CV risk 
stratification that can accurately identify high-risk asymptomatic 
dialysis patients. The challenge now is to incorporate these tests into 
clinical practice in a manner that will improve clinical outcomes. 
Combination assessment of CACS, inflammatory markers as well as 
conventional CV risk factors as summarized by FRS at the start of 
dialysis treatment may contribute to early diagnosis, prevention and 
reduction of deaths from CV disease in this population.
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